CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
<< View More Conferences
2012 Annual Meeting of the American Thyroid Association
Oncology Conference Multimedia
View more videos >>
Dr. Sherman Discusses MEK Inhibitors for Thyroid Cancer
Dr. Sippel Explains Thyroid Cancer Risk Factors
Photos From the American Thyroid Association Annual Meeting
Oncology Conference Articles
Multikinase Inhibitor Prolongs Progression-Free Survival in MTC
Cabozantinib significantly prolonged progression-free survival in medullary thyroid cancer compared with placebo among patients with radiographically confirmed progressive disease at study onset.
Panels of Molecular Markers Improve Diagnosis of Thyroid Cancer
The application of molecular markers is already significantly improving the diagnosis of thyroid cancer and broader application could help prevent unnecessary surgeries to confirm the diagnosis.
BRAF Mutational Status in Papillary Microcarcinoma: Diagnostic and Prognostic Potential
Four histopathologic features of papillary microcarcinoma help predict how aggressive the tumor will be and subsequently how aggressive treatment must be to prevent its spread.
Blanket Approach to RAI in PTC Patients May Not Be Necessary
A blanket approach to the use of radioactive iodine may not be necessary in many patients with papillary thyroid cancer provided they undergo expert total thyroidectomy first.
Disease Stabilization Now Possible in Metastatic MTC With Targeted Therapies
The availability of molecular agents that target oncogenic signaling pathways now offers the possibility of achieving disease stabilization in a proportion of patients with metastatic medullary thyroid cancer.
Initial Operation to Remove Medullary Thyroid Cancer Best Chance for Cure
The initial surgical procedure performed for the management of medullary thyroid cancer is the best chance surgeons have for a cure.
FDA Approval in CTCL, Breakthrough Therapy Designation in CRC, and More
Neoadjuvant Immunotherapy Emerges as a New Frontier
Master of the Whipple Gave Hope, Extended Lives
FDA Approves Nivolumab for Small Cell Lung Cancer
FDA Grants Full Approval to Pembrolizumab Plus Chemo for NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.